The goal of the Virginia Mason Community Clinical Oncology Program (VM-CCOP) is to improve the quality of cancer care in the Pacific Northwest through participation in cancer treatment and cancer control research. The VM-CCOP will be expanded from 3 institutions, into a network of 10 institutions stretching from Northwest to Southwest Washington. The core for the network will be the Virginia Mason Medical Center (VMMC), a regional multispecialty tertiary care medical center in Seattle, consisting of a 336-bed hospital, a 180-physician multispecialty group practice, a research center, a primary care satellite system, and a new HMO. The VM Cancer Center program features integrated multidisciplinary cancer care with a strong tradition of clinical cancer research and education. During the first 3 years of CCOP activity, the VM- CCOP developed a successful organization and data management system which accrued 180 patients on Southwest Oncology Group, Radiation Oncology Group and Fred Hutchinson Cancer Research Center protocols. The expanded VM-CCOP network will potentially provides access to urban and rural populations and a cancer patient population of 2600. The investigators, representing many disciplines involved in cancer care, have extensive experience in both cancer treatment protocol research and cancer control activities and research.
Specific aims for this renewal application include: 1) A significant increase. In patient accrual to cancer treatment protocols; 2) Create a diverse broad based population pool for participation in cancer control research; 3) Significant patient accrual to cancer control protocols; 4) Provide the operational and data management support to accomplish aims 1, 2, and 3; 5) Make available the results of the cancer treatment and cancer control research to a wide spectrum of communities; 6) Increase investigator particiaption in the scientific affairs of the research bases; 7) Promote sharing of resources and ideas within the network to improve community cancer programs. The planned expansion enables VM-CCOP to be uniquely capable of fulfilling the new CCOP goals in both cancer treatment and cancer control research.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA035192-05
Application #
3557603
Study Section
(SRC)
Project Start
1983-09-01
Project End
1990-05-31
Budget Start
1988-06-01
Budget End
1989-05-31
Support Year
5
Fiscal Year
1988
Total Cost
Indirect Cost
Name
Benaroya Research Institute at Virginia Mason
Department
Type
DUNS #
City
Seattle
State
WA
Country
United States
Zip Code
98101
Hussain, Maha; Tangen, Catherine M; Thompson Jr, Ian M et al. (2018) Phase III Intergroup Trial of Adjuvant Androgen Deprivation With or Without Mitoxantrone Plus Prednisone in Patients With High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921. J Clin Oncol 36:1498-1504
Ji, Yongli; Rankin, Cathryn; Grunberg, Steven et al. (2015) Double-Blind Phase III Randomized Trial of the Antiprogestin Agent Mifepristone in the Treatment of Unresectable Meningioma: SWOG S9005. J Clin Oncol 33:4093-8
Ramanathan, Ramesh K; McDonough, Shannon L; Kennecke, Hagen F et al. (2015) Phase 2 study of MK-2206, an allosteric inhibitor of AKT, as second-line therapy for advanced gastric and gastroesophageal junction cancer: A SWOG cooperative group trial (S1005). Cancer 121:2193-7
Mata, Douglas A; Groshen, Susan; Von Rundstedt, Friedrich-Carl et al. (2015) Variability in surgical quality in a phase III clinical trial of radical cystectomy in patients with organ-confined, node-negative urothelial carcinoma of the bladder. J Surg Oncol 111:923-8
Persky, Daniel O; Miller, Thomas P; Unger, Joseph M et al. (2015) Ibritumomab consolidation after 3 cycles of CHOP plus radiotherapy in high-risk limited-stage aggressive B-cell lymphoma: SWOG S0313. Blood 125:236-41
Goldkorn, Amir; Ely, Benjamin; Tangen, Catherine M et al. (2015) Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: a phase III metastatic castration resistant prostate cancer trial. Int J Cancer 136:1856-62
Blumenthal, Deborah T; Rankin, Cathryn; Stelzer, Keith J et al. (2015) A Phase III study of radiation therapy (RT) and O?-benzylguanine + BCNU versus RT and BCNU alone and methylation status in newly diagnosed glioblastoma and gliosarcoma: Southwest Oncology Group (SWOG) study S0001. Int J Clin Oncol 20:650-8
von Rundstedt, Friedrich-Carl; Mata, Douglas A; Groshen, Susan et al. (2015) Significance of lymphovascular invasion in organ-confined, node-negative urothelial cancer of the bladder: data from the prospective p53-MVAC trial. BJU Int 116:44-9
Gralow, Julie R; Barlow, William E; Lew, Danika et al. (2014) A phase II study of docetaxel and vinorelbine plus filgrastim for HER-2 negative, stage IV breast cancer: SWOG S0102. Breast Cancer Res Treat 143:351-8
Yao, S; Sucheston, L E; Zhao, H et al. (2014) Germline genetic variants in ABCB1, ABCC1 and ALDH1A1, and risk of hematological and gastrointestinal toxicities in a SWOG Phase III trial S0221 for breast cancer. Pharmacogenomics J 14:241-7

Showing the most recent 10 out of 131 publications